The search for a cure for Alzheimer’s disease is becoming increasingly intense and controversial, with numerous significant debates emerging in recent years.
In July 2022, Science magazine reported that a pivotal 2006 research paper in the journal Nature, which linked a brain protein called beta-amyloid to Alzheimer’s, might have involved fabricated data.
A year prior, in June 2021, the US Food and Drug Administration approved aducanumab, a drug targeting beta-amyloid, for Alzheimer’s treatment, despite mixed and incomplete data backing its efficacy.
Opinions among doctors are split; some argue it was a mistake to approve aducanumab, while others propose it should have been given a fair shot.
With a vast number of individuals needing a viable treatment, one might wonder why researchers still seem to be grappling with finding a solution for such a critical illness facing humanity.
Breaking Free from the Beta-Amyloid Focus
For quite some time, scientists have devoted themselves to creating treatments for Alzheimer’s, primarily by trying to hinder the formation of harmful beta-amyloid protein clumps.
It seems we’ve kind of trapped ourselves in this singular line of thinking, mostly overlooking other potential explanations.
Unfortunately, this obsession with studying these protein aggregates hasn’t really led to effective therapies. There’s a growing recognition that we need to think differently about Alzheimer’s.
In my lab at the Krembil Brain Institute, we’re working on a new theory regarding Alzheimer’s disease.
Drawing from three decades of research, we’re beginning to see Alzheimer’s not just as a brain issue, but rather as a disruption of the brain’s immune system.
The immune system, found throughout the body, comprises cells and molecules that operate together to heal injuries and fend off intruders.
For instance, when a person falls, the immune system promotes healing of the injured areas. Similarly, in brain trauma or infections, the brain’s immune mechanisms spring into action to repair or combat.
Considering Alzheimer’s as an Autoimmune Disease
We propose that beta-amyloid isn’t an abnormal protein but rather a naturally occurring element in the brain’s immune response. It’s meant to be there.
When trauma or bacterial presence occurs in the brain, beta-amyloid plays a vital role in the brain’s defense mechanisms. That’s where things become problematic.
Because of notable similarities between the fats composing bacterial membranes and those of brain cells, beta-amyloid struggles to distinguish between harmful invaders and the neurons it’s meant to safeguard, leading to damage to the very cells it should protect.
This misdirected immune response contributes to a steady decline in brain cell functionality, ultimately resulting in dementia—because the immune system can’t tell friend from foe.
Viewing Alzheimer’s through the lens of an immune misfire gives it the characteristics of an autoimmune condition.
There are various autoimmune disorders, like rheumatoid arthritis, where autoantibodies significantly contribute to the disease’s progression, and steroid treatments can be beneficial. However, those solutions won’t apply to Alzheimer’s.
The brain is unique, often regarded as the most complex structure in the Universe.
According to our theory, while beta-amyloid exists to reinforce the immune system, it also plays an unfortunate role in the autoimmune processes we believe may lead to Alzheimer’s.
Though conventional autoimmune drugs aren’t applicable to Alzheimer’s treatment, we’re convinced that targeting different immune-regulating pathways in the brain may lead us to effective treatment methods.
Exploring Other Theories of Alzheimer’s
Alongside this autoimmune perspective, many alternative theories about Alzheimer’s are emerging. Some researchers suggest that mitochondria—tiny structures essential for energy production in brain cells—may play a role.
Mitochondria convert oxygen and glucose into the energy vital for our thought processes and memory.
Others propose that certain brain infections, particularly those involving bacteria from the mouth, may contribute to the disease’s onset. Furthermore, some think that an improper handling of metals, such as zinc or copper, might be a factor.
Seeing all this new thinking about a long-standing disease is encouraging. Globally, more than 50 million people are affected by dementia, with a new case diagnosed every three seconds.
People suffering from Alzheimer’s often can’t recognize their children or even their long-time partners.
Alzheimer’s represents a public health challenge that demands innovative approaches and fresh perspectives.
For the benefit of individuals and families living with dementia, as well as for the overall strain on our already burdened healthcare system, a better understanding of Alzheimer’s, its causes, and potential treatments is essential.
